Corpus Intelligence IC Memo — MEYERSDALE COMMUNITY HOSPITAL 2026-04-26 23:27 UTC
IC Memo — MEYERSDALE COMMUNITY HOSPITAL
Investment Committee Memorandum | PA | 20 beds | Grade D | EBITDA uplift $1.2M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 391302

MEYERSDALE COMMUNITY HOSPITAL

LOCATIONSOMERSET, PA·BEDS20·AS OFApril 26, 2026
D
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

MEYERSDALE COMMUNITY HOSPITAL is a 20-bed community hospital in SOMERSET, PA with $16.9M in net patient revenue and a -16.3% operating margin. The hospital serves a payer mix of 37.6% Medicare, 0.0% Medicaid, and 62.4% commercial.

Thesis: Turnaround. Our ML models identify $1.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -16.3% to -9.0% (+736bps).

Net Revenue HCRIS$16.9M
Current EBITDA COMPUTED$-2.8M
Operating Margin COMPUTED-16.3%
Occupancy HCRIS30.6%
Revenue / Bed COMPUTED$846K
Net-to-Gross HCRIS48.0%
Distress Probability MLnan%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
46
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -16.3% places it below the state median. Among 46 size-comparable peers (10-40 beds), the median margin is 0.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-40), prioritizing same-state peers. 46 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MEYERSDALE COMMUNITY HOSPITAL (Target)PA20$16.9M-16.3%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%
WELLSPAN SURGERY AND REHAB HOSPA25$120.2M2.8%
UPMC LITITZPA36$114.5M14.2%
LVH-COORDINATED ALLENTOWNPA20$89.6M2.3%
CHARLES COLE MEMORIAL HOSPITALPA25$88.1M-9.0%
POCONO MEDICAL CENTER DICKSON PA40$85.9M0.1%
WELLSBOROPA25$85.6M2.3%
GEISINGER BLOOMSBURG HOSPITALPA40$75.3M6.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$355K+210bp18mo
Cost to Collect4.5%2.5%$338K+200bp12mo
Denial Rate Reduction12.0%6.5%$335K+198bp12mo
A/R Days Reduction5200.0%3800.0%$206K+122bp9mo
Clean Claim Rate88.0%96.0%$11K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$355K
Cost to Collect
$338K
Denial Rate Reduction
$335K
A/R Days Reduction
$206K
Clean Claim Rate
$11K
Total EBITDA Uplift$1.2M
Current EBITDA$-2.8M
+ RCM Uplift+$1.2M
Pro Forma EBITDA$-1.5M
Current Margin-16.3%
Pro Forma Margin-9.0%
WC Released (1x)$649K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-4.3M$-5.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-4.3M$-7.8M0.00x-100.0%
Bull Case9.0x11.0x$-3.8M$-5.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-3.8M$-6.6M0.00x-100.0%
Bear Case11.0x10.0x$-4.7M$-10.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-4.7M$-13.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 30.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 46 hospitals with 10-40 beds
  • Same-state prioritization (n=47)
  • Comp margins: P25=-11.8% / P50=0.4% / P75=7.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.